- Home
- CIGI vs LEGN Comparison
CIGI vs LEGN Comparison
Compare CIGI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGI
- LEGN
- Stock Information
- Founded
- CIGI 1972
- LEGN 2014
- Country
- CIGI Canada
- LEGN United States
- Employees
- CIGI N/A
- LEGN N/A
- Industry
- CIGI
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CIGI
- LEGN Health Care
- Exchange
- CIGI Nasdaq
- LEGN Nasdaq
- Market Cap
- CIGI 7.4B
- LEGN 7.0B
- IPO Year
- CIGI N/A
- LEGN 2020
- Fundamental
- Price
- CIGI $125.50
- LEGN $39.70
- Analyst Decision
- CIGI Buy
- LEGN Strong Buy
- Analyst Count
- CIGI 6
- LEGN 12
- Target Price
- CIGI $165.50
- LEGN $79.50
- AVG Volume (30 Days)
- CIGI 147.6K
- LEGN 976.3K
- Earning Date
- CIGI 02-06-2025
- LEGN 03-10-2025
- Dividend Yield
- CIGI 0.24%
- LEGN N/A
- EPS Growth
- CIGI 127.75
- LEGN N/A
- EPS
- CIGI 3.22
- LEGN N/A
- Revenue
- CIGI $4,822,024,000.00
- LEGN $520,183,000.00
- Revenue This Year
- CIGI $12.21
- LEGN $121.13
- Revenue Next Year
- CIGI $5.51
- LEGN $65.25
- P/E Ratio
- CIGI $39.32
- LEGN N/A
- Revenue Growth
- CIGI 11.23
- LEGN 122.96
- 52 Week Low
- CIGI $101.01
- LEGN $30.17
- 52 Week High
- CIGI $156.96
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- CIGI 32.48
- LEGN 64.82
- Support Level
- CIGI $129.79
- LEGN $34.36
- Resistance Level
- CIGI $132.32
- LEGN $36.39
- Average True Range (ATR)
- CIGI 4.22
- LEGN 1.67
- MACD
- CIGI -1.15
- LEGN 0.34
- Stochastic Oscillator
- CIGI 6.30
- LEGN 94.68
About CIGI Colliers International Group Inc. Subordinate Voting Shares
Colliers International Group Inc is a real estate services and investment management company. The company provides commercial real estate professional services and investment management to corporate and institutional clients around the world. It's primary service lines are Outsourcing & Advisory, Investment Management, Leasing and Capital Markets. Operationally, company is organized into four distinct segments: Americas; Europe, Middle East and Africa, Asia and Australasia and Investment Management.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.